You are now leaving GSK’s website

You are now leaving a GSK Website. By clicking this link, you will be taken to a website that is not owned or controlled by GSK, and GSK is not responsible for the content provided on that site

Continue

Go back

Image looking at a urinal and out of a plane window

Benign Prostatic Hyperplasia (BPH)

GSK’s commitment to research in urology and benign prostatic hyperplasia (BPH) has helped to improve the lives of patients throughout the world, with more than 20 years’ experience of aiding patients and physicians in the management of this disease.1

As part of this commitment, we are dedicated to providing the most comprehensive and up-to-date information on BPH to healthcare professionals.

00:00
00:00
00:00
00:00
00:00
00:00
GSK is committed to BPH research and education for better patient outcomes

BPH Management

Find out about treatments available for BPH patients

Resources

Visit our resources section for educational and expert videos on key topics

Efficacy

Find out about the efficacy profile for combination therapy

Safety

Find out about the safety profile for combination therapy

Prescribing Information

Duodart Prescribing information

Optional secondary information

open

Avodart Prescribing information

Optional secondary information

open

Need more help?

Request a contact

From a sales representative

Stay informed

Get the latest updates from GSK

Abbreviations

LUTS/BPH, lower urinary tract symptoms secondary to BPH.

Reference

  1. Avodart Highlights of Prescribing Information 2001 (revised 2020). Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/021319s032lbl.pdf. Accessed September 2022.

All trademarks are the property of their respective owners.

Date of preparation: January 2024
PM-SG-DTT-WCNT-230001